CClinicalTrials.gg
RecruitingNCT06624618RADOSUpdated Oct 3, 2024

Rapid Molecular Diagnosis of Sepsis in the Intensive Care Unit

An observational study in Sepsis and Bloodstream Infection, sponsored by Maastricht University Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-03.

Sponsored by Maastricht University Medical Center · Observational

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 5 months later.
Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Study summary

Rapid diagnosis of sepsis is crucial for treatment and survival. Currently, blood culture takes 48 hours-5 days to complete. After starting antimicrobial treatment blood culture results are not reliable. As a result, empirical broad spectrum antimicrobial therapy is mostly used. This implies possible antimicrobial over- or under treatment which is associated with increased antimicrobial resistance development. Early identification of the causative pathogen of sepsis will therefore have a major impact on the adequate treatment and reduction of high mortality rates. To date, there is not a single molecular diagnostic test available on the market to detect all putative causative bacterial pathogens of sepsis. In this study, the investigators will develop and validate a completely new molecular sepsis approach based on pathogen DNA detection, as an alternative to culture.

02

Conditions studied

  • Sepsis
  • Bloodstream Infection

Browse trials for

Keywords

  • Culture-free
  • Whole blood
  • Molecular diagnosis
  • Sepsis
  • Bloodstream infection
  • Bacterial DNA
03

In context

Sepsis

1,899 studies on the registry are indexed under Sepsis; 462 are open to participants now.

This study's planned enrollment of 300 is above the median of 160 across 931 observational studies indexed under Sepsis.

Browse Sepsis studies →

Lead sponsor

Maastricht University Medical Center is the lead sponsor of 835 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients at the Intensive Care Unit (ICU) of Maastricht University Medical Center (MUMC) are eligible.

Inclusion criteria

-Patients are included when routine blood cultures are ordered for diagnosis of bloodstream infections.

Exclusion criteria

Exclusion Criteria:

-N/A

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Development and validation of rapid diagnostics tests for detection of bacterial DNA in sepsis

    The tests will report presence of bacterial DNA by giving a specific bacterial species name.

    Time frame: 2 years

  2. Patterns of bacterial DNA dynamics over time

    Use of species-specific qPCR primers (either from existing sepsis literature or to be designed) to quantify the DNA load at at least 3 different time points during an infectious episode. Comparison of these loads with infectious parameters used for routine diagnostics and with antibiotic use.

    Time frame: 2 years

Secondary outcomes

  1. Distinguishing between the causative pathogen and contamination by a physician evaluation panel, both for the current gold standard (blood cultures) and the results of new microbiological tests for detecting sepsis pathogens

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • Maastricht University Medical Center
    Maastricht, Limburg 6229 HX, Netherlands
    • Anna Wijen, Msc · Contact · anna.wijen@maastrichtuniversity.nl · 0031626882868
    • Paul Savelkoul, Prof. Dr. · Contact · paul.savelkoul@mumc.nl · 0031433876644
    • Paul Savelkoul, Prof. Dr. · Contact
    • Anna Wijen, Msc · Contact
    • Christian von Wintersdorff, Dr. · Contact
    • Rob Driessen, Dr. · Contact
    • Dennis Bergmans, Dr. · Contact
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06624618
Lead sponsor
Maastricht University Medical Center
Collaborators
Health Holland
Responsible party
Sponsor
First posted
Oct 3, 2024
Start date
May 1, 2024
Primary completion
May 1, 2026 (estimated)
Completion
May 1, 2026 (estimated)
Last update
Oct 3, 2024

Study contacts

Anna Wijen, Msc.
Contact
anna.wijen@maastrichtuniversity.nl
+31 626882868
Paul Savelkoul, Prof. Dr.
Contact
paul.savelkoul@mumc.nl
+31 433876610

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion